Izinyango zokwelapha kwi-Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (i- IPF ) ayiphilwanga, kodwa iyaphathwa. Ngombulelo, amatsha amachiza avunyelwe ukususela ngo-2014 okwenza umehluko kwiimpawu , umgangatho wobomi kunye nenkqubela phambili kubantu abaphila nesifo. Ngokwahlukileyo, imichiza esetyenzisiweyo kude kube kutshanje ithathwa njengobangela obunobungozi ngaphezu kokulungileyo kwabanye abantu abane-IPF.

Ukuba uye wafumanisa ukuba unesi sifo, qiniseka ukuba ungadikibala ngolwazi oludala.

Iinjongo zoLonyango lwe-Idiopathic Pulmonary Fibrosis

Umonakalo owenzeke kwi-IPF ngencazelo engenakuphikiswa; i-fibrosis (inqununu) eyenziweyo ayikwazi ukuphiliswa. Ngoko ke, iinjongo zonyango zi:

Ekubeni i-IPF sisifo esingavamile, kuyincedo ukuba izigulana zifuna ukunyamekela kwiziko lezonyango elithe ngqo kwi-idiopathic pulmonary fibrosis kunye nesifo se-pulmatic disease. Ingcali mhlawumbi inolwazi olusandul 'ukutsha lwezinto zokwelapha olukhoyo kwaye lunokukunceda ukuba ukhethe enye into efanelekileyo kwiimeko zakho.

Imithi ye-Idiopathic Pulmonary Fibrosis

ITyrosine Kinase Inhibitors

Ngo-Oktobha ka-2014, amayeza emibini abe yilezi ziyobisi ezivunywa yi-FDA ngokukhethekileyo kunyango lwe-idiopathic pulmonary fibrosis. La mayeza, i-pirfenidone ne-nintedanib, ijolise ku-enzymes ebizwa ngokuba yi-tyrosine kinase kwaye isebenza ngokunciphisa i-fibrosis (i-antifibrotics).

Ngokulula kakhulu, i-tyrosine kinase i-enzymes iququzelele izinto zokukhula ezibangelwa i-fibrosis, ngoko ke la mayeza anqanda i-enzyme kwaye ngoko ke ukukhula okuza kubangela i-fibrosis.

Ezi zonyango ziye zafunyanwa zinenzuzo ezininzi:

Ezi zonyango zixhomekeke kakuhle, nto ibaluleke kakhulu kwisifo esiqhubekayo ngaphandle kokunyanga; uphawu oluqhelekileyo oluba yisifo sohudo.

N-Acetylcysteine

Kwixesha elidlulileyo i-acetylcysteine ​​yayisoloko isetyenziselwa ukuphatha i-IPF, kodwa uphando olutshanje lungafumananga oku kusebenza. Xa kuphulwe phantsi kubonakala ukuba abantu abaneentlobo zemizimba bangaphucula kwiyeza, ngelixa abanye abanomnye uhlobo lwemizi (enye i-allele) bakwenzakaliswe yiyobisi.

Proton Pump Inhibitors

Inomdla omnye uphando owenziwe usebenzisa i-esomeprazole, iproton pump inhibitor , kumaseli emiphunga kwibhuyibhile kunye neerati. La mayeza, aqhelekileyo asetyenziswe ukunyanga kwesifo se-reflux ye-gastroesophageal, kubangele ukwanda komzimba kumaseli emaphaphu nakwiigundane. Ekubeni i-GERD isandulela esiqhelekileyo kwi-IPF, kucinga ukuba i-asidi esiswini esisindayo kwimiphunga ingaba yinxalenye ye-etiology ye-IPF.

Ngoxa le nto ingasayi kuvavanywa kubantu, ngokuqinisekileyo unyango lwe-GERD engapheliyo kubantu abane-IPF kufuneka kuqwalaselwe.

Ukuguqulwa kwe-Lung Transplant

Ukusetyenziswa kokutshintshwa kwemiphunga okanye eminye imiphunga njengoko unyango lwe-IPF luye landa ngokuqhubekayo kwiminyaka eyi-15 edluleyo kwaye limele iqela elikhulu labantu abalinde ukunyuka kwemiphunga e-United States. Inomngcipheko omkhulu kodwa yodwa yonyango eyaziwayo ngeli xesha ukubonisa ixesha elide lokuphila.

Okwangoku, ukusinda komlambo (ixesha emva kokuba isiqingatha sabantu beswele kwaye isiqingatha sisaphila) yiminyaka engama-4.5 kunye nokutshintshwa, nangona kunjalo ukuba kusinda kuphuculwe ngeli xesha ngelixa unyango luya phambili.

Umlinganiselo wokusinda uphezulu ukudluliselwa kwamanye amazwe kunokuba uphendule enye imiphunga, kodwa ucinga ukuba oku kuhambelana nemeko engaphandle kokutsalwa, njengeziganeko zabantu ababenomnye okanye ezimbini.

Unyango o luxhasa

Ekubeni i-IPF isifo esiqhubekayo, unyango oluxhasayo ukuqinisekisa ukuba umgangatho obalulekileyo wokuphila ubaluleke kakhulu. Ezinye zale nyathelo ziquka:

Iimeko kunye neengxaki ezikhoyo

Zininzi iingxaki eziqhelekileyo kubantu abahlala ne-IPF. Ezi ziquka:

Emva kokuba ufumene i-IPF , kufuneka uxoxe ngeengxaki zezo ngxaki kunye nogqirha wakho kwaye ucwangcise icebo malunga nendlela onokuyilawula kakuhle okanye uyayikhusela.

Amaqela ezenkxaso kwi-Intanethi kunye namaLuntu

Akukho nto efana nokuthetha nomnye umntu olwa nesifo esifana nawe. Nangona kunjalo, ekubeni i-IPF ayiqhelekanga, kungenzeka ukuba ayikho iqela lokuxhasa eluntwini. Ukuba ufumana unyango kwiziko elithe ngqo kwi-IPF, kunokubakho amaqela enkxaso-mntu ekhoyo kwiziko lakho lonyango.

Kulabo abangenayo iqela leenkxaso ezifana nale-mhlawumbi ithetha ukuba abantu abaninzi abanamaqela axhasa i-IPF-intlalo kunye noluntu lukhetho olukhulu. Ukongezelela, ezi ngingqi ziyakwazi ukufumana iintsuku ezisixhenxe ngeveki, iiyure ezingama-24 ngosuku xa ufuna ukuchukumisa isiseko nomntu.

Amacandelo enkxaso anceda ekubolekeni inkxaso yabantu abaninzi kunye neendlela zokuqhubeka nokufunyanwa kwangoko kunye neyeza zonyango. Imizekelo yezinto onokuzibandakanya ziquka:

ILizwi

Ukugxekwa kwe-idiopathic pulmonary fibrosis kuyahluka kakhulu, kunye nabanye abantu abanezifo ezihamba phambili ngokukhawuleza, kunye nabanye abahlala bezinzile iminyaka emininzi. Kunzima ukuqikelela ukuba yeyiphi ikhosi iya kuba nayo nayiphi na isigulane. Isilinganiso sokusinda komdla sasingama-3.3 iminyaka ngo-2007 ngokuchasene neminyaka eyi-3.8 ngo-2011. Olunye uphando lubonise ukuba abantu abaneminyaka engama-65 nangaphezulu baphila ixesha elide kunye ne-IPF ngo-2011 kunokuba babekho ngo-2001.

Ngaphandle kweemichiza ezandisiweyo, ukunyamekela kubonakala kuphucula. Musa ukuxhomekeka kwingcaciso endala oyifumanayo, okungenzeka ingekho kumhla. Thetha nogqirha wakho malunga neenketho ezichazwe apha kwaye okulungileyo kuwe.

Imithombo:

Antoniou, K., Tomassetti, S., Tsitoura, E., noCancheri. Idiopathic pulmonary fibrosis nomdlavuza wamaphaphu: ukuhlaziywa kweklinikhi kunye ne-pathogenesis. Iingcamango zangoku kwiMithi yePulmonary . 2015 Sep 18. (Epub ngaphambi kokuprinta).

kaBoer, K., noJee Lee. Ukungabonakali kwamandla angaphantsi kwe-idiopathic pulmonary fibrosis: ukuhlaziywa. Ukuhlaselwa . 2015 Sep 13. (Epub phambi kokuprinta).

O'Riordan, T., Smith, V., kunye noG. Raghu. Ukuphuhliswa kweeNvevel Agents ze-Idiopathic Pulmonary Fibrosis: inkqubela phambili ekukhetheni okujoliswe kuyo kunye nokuqulunqwa kwesilingo. Esifubeni . 2015 Meyi 8. (Epub phambi kokuprinta).

Raghu, G. et al. Ukuxilongwa kwe-idiopathic pulmonary fibrosis ene-CT-resolution solution kwizigulane ezinobungqina obuncinane okanye obungenasifo se-radiological of honeycombing: uhlalutyo lwesekondari lolu vavanyo olulinganisiweyo. I-Lancet yeMicrosoft Respiratory Medicine . 2014. 2 (4): 277-84.

Spagnolo, P., Maher, T., noL. Richeldi. Idiopathic pulmonary fibrosis: Ukuqhubela phambili kwindlela yokwelapha i-pharmacological. Pharmacology & Therapeutics . 2015. 152: 18-27.